NGS products
Next generation sequencing (NGS) can detect and analyze the gene status of tumor driver genes, tumor suppressor genes, prognosis-related genes, and genetic susceptibility genes at the molecular level through high-throughput sequencing, thereby helping pat
Products
Prostate Cancer Genetic Testing
OncoCruise prostate cancer genetic testing
Product Description
Using probe hybridization capture technology and lllumina high-throughput rigid sequencing method, the whole exon region and some intronic regions of targeted drugs, drug resistance, prognosis, immunotherapy (MSI) and genetic related genes were detected from prostate cancer clinical treatment needs to provide a reference for prostate cancer patients.
Clinical Significance
Targeted drug use guidance: We will cover the genes recommended by guidelines and consensus for PARP inhibitors in prostate cancer, as well as genes related to approved drugs and drugs in clinical trials.
Endocrine therapy drug resistance exploration: Zhai covers genes related to endocrine therapy that are clinically recognized and frequently reported in heavyweight studies, covering mutations, amplifications and other variant types.
Immunotherapy efficacy reference: We cover MSI and positive and negative immunotherapy-related genes, and provide reference for immunotherapy efficacy.
Assessment of genetic and prognostic risk: The genes recommended by the consensus of various guidelines and clinically recognized genes of genetic and prognostic relevance are covered.
Test content
Sampling Guidelines
